• 1
    Engels EA,Pfeiffer RM,Goedert JJ, et al. Trends in cancer risk among people with AIDS in the United States 1980–2002. AIDS. 2006; 20: 16451654.
  • 2
    RiesLAG,MelbertD,KrapchoM,MariottoA,MillerBA,FeuerEJ, et al., editors. SEER Cancer Statistics Review, 1975–2004. Bethesda, MD: National Cancer Institute, 2007. Available at URL:, based on November 2006 SEER data submission, posted to the SEER Web site, 2007.
  • 3
    Von Roenn JH. Clinical presentations and standard therapy of AIDS-associated Kaposi's sarcoma. Hematol Oncol Clin North Am. 2003; 17: 747762.
  • 4
    Bubman D,Cesarman E. Pathogenesis of Kaposi's sarcoma. Hematol Oncol Clin North Am. 2003; 17: 717745.
  • 5
    Krown SE. Therapy of AIDS-associated Kaposi's sarcoma: targeting pathogenetic mechanisms. Hematol Oncol Clin North Am. 2003; 17: 763783.
  • 6
    Hong YK,Foreman K,Shin JW, et al. Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma-associated herpesvirus. Nat Genet. 2004; 36: 683685.
  • 7
    Wang HW,Trotter MW,Lagos D, et al. Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. Nat Genet. 2004; 36: 687693.
  • 8
    Pantanowitz L,Dezube BJ,Hernandez-Barrantes S,Tahan SR,Dabbous MK. Matrix metalloproteinases in the progression and regression of Kaposi's sarcoma. J Cutan Pathol. 2006; 33: 793798.
  • 9
    Toschi E,Barillari G,Sgadari C, et al. Activation of matrix-metalloproteinase-2 and membrane-type-1-matrix-metalloproteinase in endothelial cells and induction of vascular permeability in vivo by human immunodeficiency virus-1 Tat protein and basic fibroblast growth factor. Mol Biol Cell. 2001; 12: 29342946.
  • 10
    Blankaert D,Simonart T,Van Vooren JP, et al. Constitutive release of metalloproteinase-9 (92-kd type IV collagenase) by Kaposi's sarcoma cells. J Acquir Immune Defic Syndr Hum Retrovirol. 1998; 18: 203209.
  • 11
    Meade-Tollin LC,Way D,Witte MH. Expression of multiple matrix metalloproteinases and urokinase type plasminogen activator in cultured Kaposi sarcoma cells. Acta Histochem. 1999; 101: 305316.
  • 12
    Ensoli B,Gendelman R,Markham P, et al. Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma. Nature. 1994; 371: 674680.
  • 13
    Albini A,Fontanini G,Masiello L, et al. Angiogenic potential in vivo by Kaposi's sarcoma cell-free supernatants and HIV-1 tat product: inhibition of KS-like lesions by tissue inhibitor of metalloproteinase-2. AIDS. 1994; 8: 12371244.
  • 14
    Hidalgo M,Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst. 2001; 93: 178193.
  • 15
    Wojtowicz-Praga SM,Dickson RB,Hawkins MJ. Matrix metalloproteinase inhibitors. Invest New Drugs. 1997; 15: 6175.
  • 16
    Wojtowicz-Praga S,Low J,Marshall J, et al. Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer. Invest New Drugs. 1996; 14: 193202.
  • 17
    Primrose JN,Bleiberg H,Daniel F, et al. Marimastat in recurrent colorectal cancer: exploratory evaluation of biological activity by measurement of carcinoembryonic antigen. Br J Cancer. 1999; 79: 509514.
  • 18
    Rosemurgy A,Harris J,Langleben A,Casper E,Goode S,Rasmussen H. Marimastat in patients with advanced pancreatic cancer: a dose-finding study. Am J Clin Oncol. 1999; 22: 247252.
  • 19
    Investigator brochure, matrix metalloproteinase inhibitor (MMPI), BMS-275291. Bristol-Myers Squibb, Wallingford, CT. 1999.
  • 20
    Chirivi RG,Garofalo A,Crimmin MJ, et al. Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int J Cancer. 1994; 58: 460464.
  • 21
    Naglich JG,Jure-Kunkel M,Gupta E, et al. Inhibition of angiogenesis and metastasis in 2 murine models by the matrix metalloproteinase inhibitor, BMS-275291. Cancer Res. 2001; 61: 84808485.
  • 22
    Rizvi NA,Humphrey JS,Ness EA, et al. A phase I study of oral BMS-275291, a novel nonhydroxamate sheddase-sparing matrix metalloproteinase inhibitor, in patients with advanced or metastatic cancer. Clin Cancer Res. 2004; 10: 19631970.
  • 23
    Chadburn A,Hyjek E,Mathew S,Cesarman E,Said J,Knowles DM. KSHV-positive solid lymphomas represent an extra-cavitary variant of primary effusion lymphoma. Am J Surg Pathol. 2004; 28: 14011416.
  • 24
    Gold R,Schmied M,Giegerich G, et al. Differentiation between cellular apoptosis and necrosis by the combined use of in situ tailing and nick translation techniques. Lab Invest. 1994; 71: 219225.
  • 25
    Cianfrocca M,Cooley TP,Lee JY, et al. Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study. J Clin Oncol. 2002; 20: 153159.
  • 26
    Zeng ZS,Huang Y,Cohen AM,Guillem JG. Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9. J Clin Oncol. 2006; 14: 31333140.
  • 27
    Azzam HS,Arand G,Lippman ME,Thompson EW. Association of MMP-2 activation potential with metastatic progression in human breast cancer cell lines independent of MMP-2 production. J Natl Cancer Inst. 1993; 85: 17581764.
  • 28
    Brown PD,Bloxidge RE,Stuart NS,Gatter LC.Carmichael J. Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma. J Natl Cancer Inst. 1993; 85: 574578.
  • 29
    Bramhall SR,Rosemurgy A,Brown PD,Bowry C,Buckels JA,Marimastat Pancreatic Cancer Study Group. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol. 2001; 19: 34473455.
  • 30
    Erlichman C,Adjei AA,Alberts SR, et al. Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566. Ann Oncol. 2001; 12: 389395.
  • 31
    Rudek MA,Figg WD,Dyer V, et al. Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer. J Clin Oncol. 2001; 19: 584592.
  • 32
    Lara PNJr,Stadler WM,Longmate J, et al. A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases. Clin Cancer Res. 2006; 12: 15561563.
  • 33
    Daniels R,Gupta E,Kollias G, et al. Safety and pharmacokinetics of BMS-275291, a novel matrix metalloproteinase inhibitor in healthy subjects. Proc Am Soc Clin Oncol. 2001; 20: 100a. Abstract 395.
  • 34
    Miller KD,Saphner TJ,Waterhouse DM, et al. A randomized phase II feasibility trial of BMS-275291 in patients with early stage breast cancer. Clin Cancer Res. 2004; 10: 19711975.
  • 35
    Dezube BJ,Krown SE,Lee JY,Bauer K,Aboulafia DM. Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase II AIDS Malignancy Consortium Study. J Clin Oncol. 2006; 24: 13891394.